**Additional file 4: Supplemental Table 3. Methods of VTE prophylaxis and treatment in women with endometrial cancer (based on HIRA claims data for 2009-2018).**

|  |  |  |
| --- | --- | --- |
| 　 | Prophylaxis (n=3,811) | Treatment (n=357) |
| UFH | 2,972 (78.0) | 172 (48.2) |
| LMWH | 452 (11.9) | 74 (20.7) |
| Fondaparinux | 3 (0.1) | 0 (0) |
| Warfarin | 598 (15.7) | 141 (39.5) |
| DOAC | 629 (16.5) | 211 (59.1) |
| Aspirin |  | 159 (44.5) |
| Thrombectomy |  | 3 (0.8) |
| Thromboplasty |  | 0 (0) |
| Thrombolysis |  | 2 (0.6) |
| IVC filter | 　 | 21 (5.9) |

DOAC, direct oral anticoagulants; IVC, Inferior Vena Cava; LMWH, low molecular weight heparin; UFH, unfractionated heparin; VTE, venous thromboembolism.

All values ​​are expressed as number (%).